Eli Lilly’s deals add late- and early-stage vaccine assets: a potentially better-tolerated shingles candidate, bacterial ...

The rarity of sarcoma complicates clinical trial design and biomarker-driven treatment, explains Alexander Spira, MD, PhD, ...

Minhee Kang, PharmD, discusses 3 key considerations for oncology pharmacists to improve treatment safety, patient education, ...

IDOV-Safe leverages an unusually high extracellular enveloped virion proportion (~60%) to support true intravenous oncolytic virus delivery despite circulating neutralizing proteins. The phase 1 ...

The STAND Act (HR 6835) expands spinal cord injury care via annual preventive evaluations and improved access to prosthetics and assistive mobility devices for eligible veterans. The Travel Assistance ...

Pediatric cancer hospitalizations are approximately 2.5 times costlier than adult admissions, reflecting longer stays and ...

This study evaluated whether adherence to a hypertension quality measure correlates with actual blood pressure control.

As oncology care becomes increasingly complex with the introduction of targeted therapies, oncology pharmacists are playing a larger role in translating emerging evidence into clinical practice. Kang: ...

Progression from F3 to cirrhosis occurred in roughly one year, contrasting STELLAR’s 13% over four years and suggesting trials may underrepresent real-world risk. Among compensated cirrhosis, 29.7% ...

Key Takeaways. Caregiver fear and availability meaningfully influence patient willingness to pursue CAR T and other immune effector therapies, contributing to persistently low uti ...

From sequencing decisions to economics of care, Adam Kittai, MD, offers a wide-ranging look at top unresolved questions in CLL treatment today. He also explored when a triplet regimen—acalabrutinib, ...

Legislation delays mandatory digital-only quality reporting for Shared Savings Program ACOs, addressing gaps in EHR/IT infrastructure that disproportionately affect smaller, rural, and independent ...